Head-to-head evidence
albuterol / budesonide vs Ciclesonide (XRP1526)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor · full Asthma pipeline
albuterol / budesonide · Airsupra
Marketed by AstraZeneca
NCT03769090 · Phase 3 · completed
Participants were randomized and quadruple-blinded across two budesonide/albuterol groups and an active albuterol comparator, with 3,132 randomized participants. The primary clinical endpoint was met for both doses: severe exacerbations occurred in 207/1,013 versus 266/1,014 participants for high-dose treatment (hazard ratio 0.733, p<0.001) and 241/1,054 versus 276/1,056 for low-dose treatment (hazard ratio 0.835, p=0.041).
Next expected readout: February 2027 · NCT06422689 (registry estimate)
Ciclesonide (XRP1526)
Developed by Sanofi
NCT00174720 · Phase 3 · completed
In this randomized, double-blind, placebo-controlled Phase 3 trial, 708 patients with asthma were randomized to one of several ciclesonide dosing regimens or placebo. Ciclesonide produced significantly greater improvements in lung function (FEV1) than placebo, both averaged over weeks 12-16 and at week 16 alone.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol / budesonide's landscape · Ciclesonide (XRP1526)'s landscape